EP1165529A1 - A process for the preparation of thiazolidine derivatives - Google Patents
A process for the preparation of thiazolidine derivativesInfo
- Publication number
- EP1165529A1 EP1165529A1 EP00909666A EP00909666A EP1165529A1 EP 1165529 A1 EP1165529 A1 EP 1165529A1 EP 00909666 A EP00909666 A EP 00909666A EP 00909666 A EP00909666 A EP 00909666A EP 1165529 A1 EP1165529 A1 EP 1165529A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- preparation
- mixture
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000003548 thiazolidines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 8
- 150000002367 halogens Chemical group 0.000 claims abstract description 8
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- -1 thiazolidine compound Chemical class 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- LGSOKZOQANLOEU-UHFFFAOYSA-N 4-[2-(2,4-dioxo-1,3-thiazolidin-5-yl)ethoxy]benzonitrile Chemical compound S1C(=O)NC(=O)C1CCOC1=CC=C(C#N)C=C1 LGSOKZOQANLOEU-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000013078 crystal Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical class C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NKALVESVNGTFHZ-UHFFFAOYSA-N 2-(2-bromoethoxy)naphthalene Chemical compound C1=CC=CC2=CC(OCCBr)=CC=C21 NKALVESVNGTFHZ-UHFFFAOYSA-N 0.000 description 1
- IVKAPFWKLFIYCG-UHFFFAOYSA-N 4-(2-bromoethoxy)benzonitrile Chemical compound BrCCOC1=CC=C(C#N)C=C1 IVKAPFWKLFIYCG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
Definitions
- the present invention relates to a process for the preparation of thiazolidine derivatives . More particularly, the present invention relates to a process for the preparation of a compound of formula ( I )
- thiazolidine derivatives including a compound of formula ( I ) reduce blood sugar level and therefore are useful for the treatment of non-insulin dependent diabetes mellitus.
- many methods for the preparation of thiazolidine derivatives are illustrated. Thereamong some of methods for the preparation of a compound of formula ( I ) are extracted in the following reaction scheme 1 and 2.
- D ring is
- A is C2-6 alkylene and X is halogen.
- R 1 is alkyl and the other symbols are as defined above.
- the present inventors investigated energetically in order to improve the problem, so that the present inventors found that in the presence of ammonia addition of an alkali metal increased the yield very much and completed the invention.
- the present invention relates to a process for the preparation of a compound of formula (I)
- A is C2-6 alkylene.), consisting of subjecting to reaction a compound of formula (II)
- reaction of preparing a compound of formula ( I ) from a compound of formula (II) and a compound of formula (V) is, for example, carried out by subjecting to reaction a compound of formula (II) and a compound of formula (V) in the presence of liquid ammonia, using an alkali metal (lithium, sodium etc.
- a compound of formula (II) which is used as a starting material in the above reaction is known and it is , for example , prepared according to the above reaction scheme 1.
- Cl-4 alkyl is methyl, ethyl, propyl, butyl and isomers thereof.
- C2-6 alkylene is ethylene, propylene, tetramethylene, pentamethylene, hexamethylene and isomers thereof.
- halogen is fluorine, chlorine, bromine and iodine.
- D ring is preferably
- A is preferably C2-3 alkylene.
- the present invention gives an excellent method in the preparation of a compound of formula ( I ) which is a target compound.
- the method of the present invention gives a compound of formula ( I ) in about two or three times as high yield as the previously known method (i.e. A compound of formula ( I ) is given about 60-90% yield by the present method; about 20-30% yield by the previous method. ) .
- the method of the present invention is more excellent than the previous method and is suitable for industrial mass synthesis.
- the solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations .
- the crystal that appeared was gathered and washed by water and ethanol successively, dried under reduced pressure to give a crude crystal.
- the crude crystal was dissolved in ethanol under refluxing condition.
- activated carbon To the mixture was added activated carbon.
- the mixture was stirred at the same temperature and filtrated with heating.
- the filtrate was stirred at ambient temperature for 5 hours.
- the crystal that appeared was filtered off and was dried under reduced pressure to give the compound of the present invention (303 g, 75% yield) having the following physical data.
- the aqueous layer was acidified by adding cone, hydrochloric acid and the mixture was extracted with ethyl acetate.
- the organic layer was washed by 2N hydrochloric acid, dried over anhydrous magnesium sulfate and was concentrated under reduced pressure.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a process for the preparation of a thiazolidine compound of formula (I): wherein D ring is (i); wherein R is hydrogen; C1-4 alkyl, halogen or cyano; or (ii) and A is C2-6 alkylene. According to the present method, a compound of formula (I) is obtained in higher yield than the previous method.
Description
DESCRIPTION
A process for the preparation of thiazolidine derivatives
Technical Field
The present invention relates to a process for the preparation of thiazolidine derivatives . More particularly, the present invention relates to a process for the preparation of a compound of formula ( I )
(wherein all symbols are as defined hereafter.) which is useful as an agent for non-insulin dependent diabetes mellitus .
Background Art
In W097/47612 specification, it is described that thiazolidine derivatives including a compound of formula ( I ) reduce blood sugar level and therefore are useful for the treatment of non-insulin dependent diabetes mellitus. In the specification many methods for the preparation of thiazolidine derivatives are illustrated. Thereamong some of methods for the preparation of a compound of formula ( I ) are extracted in the following reaction scheme 1 and 2.
In the reaction scheme 1 , D ring is
(wherein R is hydrogen, Cl-4 alkyl, halogen or cyano.) or
A is C2-6 alkylene and X is halogen. In the reaction scheme 2, R1 is alkyl and the other symbols are as defined above.
Scheme 1
Scheme 2
alcoholate (VII)
Acid hydrolysis
The methods described in the reaction scheme 1 and 2 , however, gives a compound of formula (I) in low yield, and so they are not suitable for industrial mass synthesis. For example, according to the above specification, as an Example for the reaction scheme 1, a compound of formula (1-1)
is given from a compound of formula (II-l)
in about 23% yield.
As an Example for the reaction scheme 2 , a compound of formula (1-2)
is given from a compound of formula (II-2)
in about 23 % yield.
Therefore, a method to improve chemical yield and applicable to industrial mass synthesis was hoped for.
Disclosure of Invention
The present inventors investigated energetically in order to improve the problem, so that the present inventors found that in the presence of ammonia addition of an alkali metal increased the yield very much and completed the invention.
The present invention relates to a process for the preparation of a compound of formula (I)
(wherein D ring is
(wherein R is hydrogen, Cl-4 alkyl, halogen or cyano.) or
A is C2-6 alkylene.), consisting of subjecting to reaction a compound of formula (II)
(wherein X is halogen and the other symbols are as defined above.) and a compound of formula (V)
in the presence of an alkali metal using liquid ammonia.
The reaction of preparing a compound of formula ( I ) from a compound of formula (II) and a compound of formula (V) is, for example, carried out by subjecting to reaction a compound of formula (II) and a compound of formula (V) in the presence
of liquid ammonia, using an alkali metal (lithium, sodium etc. , preferably lithium.) and a catalyst (iron (III) nitrate nonahydrate etc.), in the presence or absence of a solvent (tetrahydrofuran, diethylether, dioxane etc.) at a temperature of from -78 °C to -60 °C, preferably at a temperature of from -70 °C to -60 °C (The reaction is illustrated in Synthesis, 310 (1971).).
A compound of formula (II) which is used as a starting material in the above reaction is known and it is , for example , prepared according to the above reaction scheme 1.
In the present specification, Cl-4 alkyl is methyl, ethyl, propyl, butyl and isomers thereof.
In the present specification, C2-6 alkylene is ethylene, propylene, tetramethylene, pentamethylene, hexamethylene and isomers thereof.
In the present specification, halogen is fluorine, chlorine, bromine and iodine.
Among the compounds of formula (I) prepared by the present invention, D ring is preferably
or
Among the compounds of formula ( I ) prepared by the present invention, A is preferably C2-3 alkylene. As the compound of formula ( I ) ,
or
is preferable.
Industrial Applicability
The present invention gives an excellent method in the preparation of a compound of formula ( I ) which is a target compound. The method of the present invention gives a compound of formula ( I ) in about two or three times as high yield as the previously known method (i.e. A compound of formula ( I ) is given about 60-90% yield by the present method; about 20-30% yield by the previous method. ) .
Therefore, the method of the present invention is more excellent than the previous method and is suitable for industrial mass synthesis.
Best Mode for Carrying Out the Invention
The following examples are intended to illustrate, but do not limit, the present invention. The solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations .
Solvents in parentheses of NMR show the solvents used in measurement.
Reference Example 1
Preparation of 1- (2-bromoethyloxy) -4-cyanobenzene
To a suspension of potassium carbonate (622 g) in dibromoethane (2.5 L) under refluxing condition, was added dropwise over a period of 9 hours a solution of 4-cyanophenol (357 g) in acetonitrile (0.7 L) and the mixture was stirred for 2.5 hours . The mixture was cooled to ambient temperature and the precipitate was filtered off. The filtrate was concentrated under reduced pressure. To the residue was added ethyl acetate-hexane mixture (1.5 L, ethyl acetate: hexane = 1:2) and the mixture was stirred at ambient temperature overnight . The precipitate was removed off . Approximately half volume of the solvent of the mother solution was evaporated under reduced pressure. The crystal
was filtered off. The crystal that appeared was dried under reduced pressure to give the title compound (386 g, 63% yield) as a white crystal.
TLC : Rf 0.55 (hexane : ethyl acetate = 1:1); NMR (CDC13): δ 7.60 (d, J = 7.5 Hz, 2H) , 7.00 (d, J = 7.5 Hz, 2H), 4.35 (t, J = 5 Hz, 2H) , 3.65 (t, J = 5 Hz, 2H) .
Example 1
Preparation of 5- [2- (4-cyanophenoxy)ethyl] -thiazolidin- 2,4-dione
To liquid ammonia (2.5 L ) was added metal lithium (5.8 g) at a temperature of from -70 °C to -60 °C. To the mixture was added iron(III) nitrate nonahydrate (150 mg) . To the mixture was added metal lithium (23.3 g) and the mixture was stirred until navy blue color disappeared. To the mixture was added iron(III) nitrate nonahydrate (150 mg) and the mixture was stirred for 20 minutes. To the mixture was added 1 ,3-thiazolidin-2,4-dione (234 g) over a period of 15 minutes and the mixture was stirred for 30 minutes. To the reaction mixture was added a solution of the compound prepared in reference example 1 (348 g) in tetrahydrofuran (420 ml) over a period of 5 minutes . The reaction mixture was stirred at
a temperature of from -60 °C to -50 °C for 1 hour. To the mixture was added ammonium chloride (269 g) and the mixture was allowed to stand at ambient temperature overnight . To the residue was added water (2 L) and ethyl acetate-diethyl ether mixture (1.5 L ; ethyl acetate : diethyl ether = 1:1) and the aqueous layer was separated. Under cooling with ice, the aqueous layer was acidified to pH 2-3 by adding concentrated hydrochloric acid (2.5 L). The crystal that appeared was gathered and washed by water and ethanol successively, dried under reduced pressure to give a crude crystal. The crude crystal was dissolved in ethanol under refluxing condition. To the mixture was added activated carbon. The mixture was stirred at the same temperature and filtrated with heating. The filtrate was stirred at ambient temperature for 5 hours. The crystal that appeared was filtered off and was dried under reduced pressure to give the compound of the present invention (303 g, 75% yield) having the following physical data. TLC : Rf 0.46 (hexane : ethyl acetate = 1:1); NMR (DMSO-d6) : δ 12.20-11.90 (br.s, IH) , 7.75 (d, J = 7.5 Hz, 2H), 7.10 (d, J = 7.5 Hz, 2H) , 4.70 (dd, J = 5.0, 2.5 Hz, IH), 4.25 (t, J = 5.0 Hz, 2H) , 2.60-2.30 (m, 2H) ; IR (KBr) : 3181, 2229, 1746, 1697, 1606, 1509, 1305, 1257, 1180, 1154, 1029, 829, 669, 549 cm"1.
Reference Example 2
Preparation of 2- (2-bromoethyloxy)naphthalene
By the same procedure as described in reference example 1 using jS -naphthol in place of 4-cyanophenol, the title compound having the following physical data was given. TLC: Rf 0.50 (n-hexane : ethyl acetate = 9:1); NMR (CDC13) : δ 7.80-7.65 (m, 3H) , 7.50-7.05 (m, 4H) , 4.40 (t, 2H, J = 7 Hz), 3.70 (t, 2H, J = 7 Hz).
Example 2
Preparation of 5- [2- (naphthalen-2-yloxy)ethyl] thiazolin- 2, 4-dione
To liquid ammonia (1.5 L) at a temperature of from -70 to -60 °C, were added metal lithium (1.32 g) , iron(III) nitrate nonahydrate (35 mg) and metal lithium (5.28 g) successively and the mixture was stirred until navy blue color disappeared. To the mixture was added iron(III) nitrate nonahydrate (35 mg) and the mixture was stirred for 20 minutes . To the mixture was added 1 , 3-thiazolidin-2 , 4-dione (52.7 g) and the mixture was stirred for 30 minutes . To the reaction mixture was added
a compound prepared in reference example 2 (75.4 g) in anhydrous tetrahydrofuran (250 ml) and the mixture was stirred at ambient temperature for 2.5 hours . The mixture was cooled to -70 °C, and thereto was added ammonium chloride (50.6 g) and the mixture was allowed to stand at ambient temperature overnight . The mixture was concentrated under reduced pressure. To the residue were added n-hexane-ethyl acetate mixture (500 ml; n-hexane : ethyl acetate = 1:1) and a 5N aqueous solution of sodium hydroxide (300 ml). Under cooling with ice, the aqueous layer was acidified by adding cone, hydrochloric acid and the mixture was extracted with ethyl acetate. The organic layer was washed by 2N hydrochloric acid, dried over anhydrous magnesium sulfate and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride : ethyl acetate = 10:1). The residue was recrystallized by ethanol (400 ml) to give the compound of the present invention (56 g, 65 %) having the following physical data. TLC: Rf 0.33 (methylene chloride : ethyl acetate = 10:1); NMR (CDCl3+DMSO-d6) : δ 10.50 (br.s, IH) , 7.75 (m, 3H) , 7.44 (m, IH), 7.35 (m, IH) , 7.12 (m, 2H) , 4.51 (m, IH) , 4.32 (m, IH), 4.20 (m, IH), 2.75 (m, IH) , 2.40 (m, IH) ; IR (KBr) : 3171, 3058, 1747, 1688, 1626, 1600, 1259, 1216, 1184, 1030, 839, 752, 656 cm"1.
Claims
1. A method for the preparation of a compound of formula (I)
(wherein D ring is
(wherein R is hydrogen, Cl-4 alkyl, halogen or cyano.) or
and A is C2-6 alkylene) which is characterized by subjecting to reaction a compound of formula (II)
(wherein X is halogen and the other symbols are as defined above.) and a compound of formula (V)
in the presence of an alkali metal in liquid ammonia.
2. A method for the preparation, according to claim 1, which is characterized by using lithium as an alkali metal.
3. A method for the preparation, according to claim 1, of a compound of formula (I) wherein D ring is
and A is ethylene.
4. A method for the preparation, according to claim 1, of a compound of formula (I) wherein D ring is
and A is ethylene.
5. A method for the preparation, according to claim 1 , of 5- [ 2- ( 4-cyanophenoxy)ethyl] -thiazolidin-2,4-dione .
6. A method for the preparation, according to claim 1, of 5- [2- (naphthalen-2-yloxy)ethyl]thiazolin-2,4-dione.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7351999 | 1999-03-18 | ||
| JP7351999 | 1999-03-18 | ||
| PCT/JP2000/001595 WO2000055146A1 (en) | 1999-03-18 | 2000-03-16 | A process for the preparation of thiazolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1165529A1 true EP1165529A1 (en) | 2002-01-02 |
Family
ID=13520586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00909666A Withdrawn EP1165529A1 (en) | 1999-03-18 | 2000-03-16 | A process for the preparation of thiazolidine derivatives |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1165529A1 (en) |
| KR (1) | KR20010112328A (en) |
| CN (1) | CN1350526A (en) |
| AU (1) | AU3192400A (en) |
| BR (1) | BR0009079A (en) |
| CA (1) | CA2368146A1 (en) |
| HU (1) | HUP0200585A3 (en) |
| NO (1) | NO20014451L (en) |
| NZ (1) | NZ514177A (en) |
| TR (1) | TR200102689T2 (en) |
| WO (1) | WO2000055146A1 (en) |
| ZA (1) | ZA200107603B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2670731B1 (en) | 2011-02-02 | 2016-05-25 | Bionomics Limited | Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8919417D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| FR2749583B1 (en) * | 1996-06-07 | 1998-08-21 | Lipha | NOVEL SUBSTITUTED THIAZOLIDINE -2,4- DIONE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
-
2000
- 2000-03-16 HU HU0200585A patent/HUP0200585A3/en unknown
- 2000-03-16 KR KR1020017011662A patent/KR20010112328A/en not_active Withdrawn
- 2000-03-16 EP EP00909666A patent/EP1165529A1/en not_active Withdrawn
- 2000-03-16 BR BR0009079-4A patent/BR0009079A/en not_active IP Right Cessation
- 2000-03-16 CA CA002368146A patent/CA2368146A1/en not_active Abandoned
- 2000-03-16 TR TR2001/02689T patent/TR200102689T2/en unknown
- 2000-03-16 NZ NZ514177A patent/NZ514177A/en unknown
- 2000-03-16 AU AU31924/00A patent/AU3192400A/en not_active Abandoned
- 2000-03-16 CN CN00807522A patent/CN1350526A/en active Pending
- 2000-03-16 WO PCT/JP2000/001595 patent/WO2000055146A1/en not_active Ceased
-
2001
- 2001-09-13 NO NO20014451A patent/NO20014451L/en not_active Application Discontinuation
- 2001-09-14 ZA ZA200107603A patent/ZA200107603B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0055146A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TR200102689T2 (en) | 2002-01-21 |
| NO20014451D0 (en) | 2001-09-13 |
| ZA200107603B (en) | 2003-02-26 |
| NZ514177A (en) | 2003-04-29 |
| AU3192400A (en) | 2000-10-04 |
| HUP0200585A2 (en) | 2002-06-29 |
| WO2000055146A1 (en) | 2000-09-21 |
| BR0009079A (en) | 2002-01-02 |
| CN1350526A (en) | 2002-05-22 |
| NO20014451L (en) | 2001-11-12 |
| KR20010112328A (en) | 2001-12-20 |
| HUP0200585A3 (en) | 2004-07-28 |
| CA2368146A1 (en) | 2000-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1432682B1 (en) | Process for the preparation of repaglinide | |
| JP3450389B2 (en) | Method for producing L-5- (2-acetoxy-propionylamino) -2,4,6-triiodo-isophthalic dichloride | |
| RU2510395C2 (en) | Method of producing docetaxel | |
| RO120261B1 (en) | Process for the selective preparation of z-isomer of 3-(2-substituted vinyl)cephalosporin | |
| US5426196A (en) | Synthesis of diaryl methanes | |
| EP1165529A1 (en) | A process for the preparation of thiazolidine derivatives | |
| Srivastava et al. | N-benzoyl-(2R, 3S)-3-phenylisoserine methyl ester; a facile and convenient synthesis and resolution by entrainment | |
| MXPA01009365A (en) | A process for the preparation of thiazolidine derivatives | |
| US5665888A (en) | Protected aminothiazolylacetic acid derivatives | |
| EP1533306A1 (en) | Azlactone compound and method for preparation thereof | |
| JP2000327669A (en) | Method for producing thiazolidine derivative | |
| NZ210718A (en) | The preparation of azetidinones | |
| CN111662233B (en) | Method for synthesizing 4-chloro-1H-imidazole-2-carboxylic acid ethyl ester by one-step method | |
| CN121591669A (en) | A method for preparing a sinoamine intermediate | |
| JP2804364B2 (en) | Process for producing oximes | |
| JPH0641066A (en) | Production of pyrrole derivative | |
| JP4664903B2 (en) | Process for producing 4,10β-diacetoxy-2α-benzoyloxy-5β, 20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa [g] taxa-11-ene | |
| US5900483A (en) | Process for the separation of phenyluracil compounds | |
| JPS6110569A (en) | Preparation of 2-(2-aminothiazole)-acetic acid derivative | |
| KR20260029372A (en) | DPP1 inhibitor intermediate, method for preparing same, and use thereof in medicine | |
| JP3538889B2 (en) | Method for producing alkylthioacetamide | |
| JPH08151374A (en) | Production of 5-bromo-2-furfural derivative | |
| JP4168184B2 (en) | Method for producing N-acyl (meth) acrylamide derivative | |
| CA2017426A1 (en) | Process | |
| JPH0812658A (en) | Production of sydnones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| 17P | Request for examination filed |
Effective date: 20010914 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20030414 |